Avax, Hopital NECKER, Institut National de la Sante et de la Recherche Medicale deal

AVXT received a worldwide option from the hospital and INSERM to exclusively license their XI-SCID gene therapy technology to treat severe combined immunodeficiency. AVXT's Genopoietic S.A. subsidiary...